Crescent Biopharma posts smaller-than-expected Q2 net loss
CBIO•Cash runway outlook
- Company expects cash runway to extend into the second half of 2028.
Key details and analyst coverage
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | Beat | $24.84 mln | $25.25 mln (7 Analysts) |
| Q2 Income from Operations | Beat | -$26.36 mln | -$26.63 mln (7 Analysts) |
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the pharmaceuticals peer group is "buy".
- Wall Street's median 12-month price target for Crescent Biopharma Inc is $30.00, about 103.1% above its July 29 closing price of $14.77.
Q2 cost drivers and pipeline focus
- R&D spending - Co said higher Q2 research and development expenses were driven by increased costs for chemistry, manufacturing, controls, clinical activity and higher personnel-related costs.
- Pipeline advancement - Co cited ongoing and planned clinical trials for CR-001, CR-002 and CR-003 as key operational focus during the quarter.
- G&A costs - Co said Q2 general and administrative expenses declined due to lower personnel and professional service costs, partially offset by higher office, facilities, software and public company expenses.
